

Anthony J. Davis, Esq. (#033811992) (adavis@ogcsolutions.com)
Brian E. Moffitt, Esq. (#020831992) (bmoffitt@ogcsolutions.com)
SANTOMASSIMO DAVIS LLP
1 Gatehall Drive, Suite 100
Parsippany, New Jersey 07054
(201) 712-1616
Attorneys for Plaintiffs

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

_____)	
MSP RECOVERY CLAIMS, SERIES LLC.;)	Civil Action No. ____:21-cv-_____
MSPA CLAIMS 1, LLC; MAO-MSO)	
RECOVERY II, LLC, SERIES PMPI, a)	
segregated series of MAO-MSO RECOVERY)	
II, LLC; MSP RECOVERY CLAIMS SERIES)	
44, LLC, MSP RECOVERY CLAIMS PROV,)	
SERIES LLC, and MSP RECOVERY)	
CLAIMS CAID, SERIES LLC,)	
)	
PLAINTIFFS,)	
)	
VS.)	
)	
CELGENE CORPORATION AND BRISTOL-)	
MYERS SQUIBB COMPANY,)	
)	
DEFENDANTS.)	
_____)	

COMPLAINT

JURY TRIAL DEMANDED

Plaintiffs MSP Recovery Claims, Series LLC, MSPA Claims 1, LLC and MAO-MSO Recovery II, LLC, Series PMPI, a segregated series of MAO-MSO Recovery II, LLC, MSP Recovery Series 44, LLC, MSP Recovery Claims PROV, Series LLC, and MSP Recovery Claims CAID, Series LLC (collectively referred to as “Plaintiffs” or “MSP” unless otherwise specifically identified hereby), through its attorneys, Santomassimo Davis LLP, by way of Complaint against Defendant Celgene Corporation (“Celgene”) and Defendant Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) (collectively referred to as “Defendants”) state as follows:

I. NATURE OF THE CASE

1. Plaintiffs bring this action against Celgene and its parent Bristol-Myers Squibb for violations of consumer protection and common law claims, arising out of Celgene's anticompetitive scheme that has prevented generic brands from entering the market to compete with Celgene's high-priced drugs Thalomid and Revlimid. The improper actions described below have allowed Celgene to maintain supracompetitive prices that thwart legitimate competition that would have benefited consumers and the public at large by drastically lowering the price of these medically necessary drugs. Celgene's misconduct is a textbook example of the type that is proscribed by both federal and state law and is emblematic of the historic and unprecedented increase in pharmaceutical drug costs. Plaintiffs' allegations are made on personal knowledge as to Plaintiffs, publicly available information and upon information and belief as to all other matters.

2. The subject drug Thalomid was originally developed, marketed, and sold under the brand name Thalidomide in the late 1950s and early 1960s as a sedative and anti-nausea medication. Thalidomide had catastrophic results "[w]hen taken by pregnant women for morning sickness, it caused missing limb parts in the fetus . . . as well as organ damage and death. Fifty years after the drug's heyday, the fear it inspired haunts arguments about the safety and regulation of medications . . . That tragedy is a major reason the Food and Drug Administration has as much authority over new drugs as it does today."¹

3. In 1998, Celgene obtained U.S. Food and Drug Administration ("FDA") approval to market Thalomid® (thalidomide) for a leprosy complication known as erythema nodosum leprosum ("ENL").

4. In 2005, Celgene successfully developed a thalidomide analog, Revlimid® (lenalidomide), and obtained FDA approval to market it for a specific chromosomal variant of

¹ Amanda Schaffer, *Thalidomide's Comeback*, Slate, Jan. 10, 2011, http://www.slate.com/articles/double_x/doublex/2011/01/thalidomides_comeback.html.

myelodysplastic syndromes (“MDS”). Celgene would go on to obtain FDA approvals for additional Revlimid indications, including for a subset of multiple myeloma (“MM”) patients in 2006,² and later for a subset of mantle cell lymphoma (“MCL”) patients in 2013.

5. However, unsatisfied with profits earned within the pharmaceutical legal and regulatory framework, Celgene commenced an anticompetitive scheme to illegally monopolize the market for Thalomid and Revlimid. Celgene constructed an impenetrable monopolistic fortress and engaged in a multi-prong scheme to unlawfully maintain an 100% share of the market for these two drugs by successfully interfering with competitors’ efforts to develop and/or obtain FDA approval for generic versions of Thalomid and/or Revlimid at each progressive step of development.

6. As part of this anticompetitive scheme, plaintiffs allege that Celgene is: (1) manipulated the safety program designed to protect patients from thalidomide’s and lenalidomide’s teratogenic properties; (2) prevented pharmacies and ingredient suppliers from acting as alternative sources of samples for such would-be generic competitors; (3) fraudulently obtained various patents from the U.S. Patent and Trademark Office (“USPTO”) for Thalomid and Revlimid and their associated safety distribution protocols; (4) serially commencing “sham” patent infringement lawsuits; and (5) filed baseless citizen petitions with the FDA to stymie generic approvals.

7. In the rare instances where Celgene’s efforts failed to prevent a would-be competitor from prosecuting an Abbreviated New Drug Application (“ANDA”), and FDA approval of an ANDA for a generic version of Revlimid or Thalomid became possible, Celgene entered into confidential

² Under the FDA’s orphan drug exclusivity program, 21 U.S.C. §§ 360aa-cc, the FDA may not approve a generic equivalent for a specific indication or “rare disease” that a brand drug is FDA-approved to treat for a period of seven (7) years. MM is such a “rare disease.” Therefore, until May 25, 2013, the FDA could not approve a generic thalidomide for the treatment of MM. It could, nevertheless, approve generic thalidomide for the treatment of other indications. This is known as a “skinny label.”

settlements with its competitors that, upon information and belief, included anti-competitive “pay-for-delay” reverse payments. The federal government has routinely criticized – and challenged in court – the same sort of anticompetitive practices in which Celgene engages.³

8. In 2006, a month’s supply of Revlimid cost \$6,195.⁴ In 2010, the price was about \$8,000 for a one-month supply. Now, a twenty-eight (28) day supply of Revlimid costs patients and their health insurers as much as \$20,000, and a twenty-eight (28) day supply of Thalomid costs them as much as \$10,000. In 2016, Celgene’s total revenue was \$11.23 billion, of which \$6.97 billion was from Revlimid and \$152.10 million was from Thalomid. When Thalomid first entered the market, it cost approximately \$6 per capsule. In 2014, its price soared to as much as \$357 per capsule.

9. In the last ten (10) years, as a result of Celgene’s anticompetitive conduct to eliminate/limit generic alternatives from the market, Celgene has been able to routinely increase its prices either once or twice per year.

10. Celgene’s illicit and monopolistic efforts with respect to Thalomid and Revlimid have been enormously profitable. Between 2006 and 2016, Celgene recorded \$35.60 billion of Revlimid sales and \$3.65 billion of Thalomid sales, yielding the following respective annual sales:⁵

	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	
Revlimid	6974M	5800M	4980M	4280M	3770M	3210M	2470M	1706M	1325M	774M	321M

³ See, e.g., Federal Trade Commission, *Pay for Delay: How Drug Company Pay-Offs Cost Consumers Billions* (Jan. 2010), <https://www.ftc.gov/sites/default/files/documents/reports/pay-delay-how-drug-company-pay-offs-cost-consumers-billions-federal-trade-commission-staff-study/100112payfordelayrpt.pdf>.

⁴ Alison Kodjak, *How A Drugmaker Gamed The System to Keep Generic Competition Away* (May 17, 2018), <https://www.npr.org/sections/health-shots/2018/05/17/571986468/how-a-drugmaker-gamed-the-system-to-keep-generic-competition-away>.

⁵ Net product sales figures drawn from Celgene’s Annual Reports/Form 10-K filings for fiscal years ending 2007-2016.

Thalomid 152M 185M 221M 245M 302M 339M 387M 437M 505M 447M

11. In December 2016, Revlimid was the second-highest grossing drug worldwide.⁶ For the year ended December 31, 2020, Bristol-Myers Squibb reported that Revlimid revenue had grown to more than \$12.1 billion worldwide, including more than \$8.29 billion in the United States.⁷

12. There has never been a generic substitute for Revlimid or Thalomid available in the U.S., enabling Celgene to price the drugs at levels unrestrained by generic competition.

13. Celgene's anticompetitive tactics to block generic entry have caused Plaintiffs to pay supracompetitive prices for these drugs in violation of various federal antitrust laws, states' antitrust, consumer protection, trade practices, and insurance fraud laws.

14. Plaintiffs seek to recover incurred civil damages and over payments made on behalf of their Assignors who purchased or otherwise provided reimbursement for Thalomid and/or Revlimid, which was prescribed and dispensed to Plaintiffs' Assignors' Enrollees as well as injunctive relief.

II. JURISDICTION AND VENUE

15. This Court has jurisdiction over this action pursuant to 28 U.S.C. §§ 1331 and 1337 as well as 15 U.S.C. §§ 15 and 26. Plaintiffs assert federal claims for treble damages, injunctive relief and costs of suit, including reasonable attorneys' fees, against Defendants under Section 2 of the Sherman Act, 15 U.S.C. § 2, and Sections 4 and 16 of the Clayton Act, 15 U.S.C. §§ 15 and 26.

⁶ Amy Brown, *EP Vantage 2017 Preview* (Dec. 2016), <http://info.evaluategroup.com/rs/607-YGS-364/images/EPV2017Prev.pdf>.

⁷ <https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2020/default.aspx>.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.